Dr. El Assal is a scientist-clinician turned venture capitalist investing in healthcare and life sciences. He is the Managing General Partner & Co-founder of Boutique Venture Partners, a venture capital firm specializing in early-stage investments in Biotech, Medtech, Digital Health, Health Economics, and Health Edtech startups. At Boutique, Rami has led over a dozen investments and currently serves on the Board of Directors of Filtricine. In 2022, he was recognized among the Top 25 Healthcare Investors by Growth Cap Advisory.
Prior to founding Boutique, Rami was a Research Scientist (Academic Staff) at the Canary Center for Cancer Early Detection at Stanford University School of Medicine and is currently affiliated with the Precision Health and Integrated Diagnostic Center at Stanford University. Previously, he completed two Postdoctoral Research Fellowships at Stanford and Harvard Medical Schools. He has been recognized by several entities, such as the Center of Nanoscale Systems (CNS) at Harvard University, and published in the field of Early Detection & Early Treatment, including a two-volume book published in Springer Nature.